Roth Mkm Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX) recently received a reaffirmed "buy" rating from analysts at Roth Mkm, as reported in a research release this Tuesday. The investment firm has set a target price of $7.00 for the stock, suggesting a substantial potential upside of 340.25% based on the current stock price.

Several other analysts have shared their views on Gain Therapeutics as well. On December 5, Roth Capital upgraded the company to a "strong-buy" rating. Additionally, HC Wainwright maintained a "buy" rating on the stock with a price target of $8.00, which was announced on November 25. Currently, four analysts have given Gain Therapeutics a buy rating, while one has issued a strong buy recommendation. MarketBeat's data shows that the consensus rating for the stock is "Buy," with a consensus price target of $7.25.

Recent Stock Performance

As for the recent trading performance, Gain Therapeutics’ stock opened at $1.59 on Tuesday. The stock has a 50-day moving average price of $1.99 and a 200-day moving average price of $1.60. Gain Therapeutics boasts a low debt-to-equity ratio of 0.04 and a current and quick ratio of 2.99, indicating good financial health. Its stock has experienced a notable range over the past year, with a low of $0.89 and a high of $5.33. As of the last update, the company has a market capitalization of $42.17 million and a price-to-earnings ratio of -1.45, alongside a beta of 0.21, suggesting lower volatility compared to the wider market.

Institutional Investment Trends

Recent activity from hedge funds shows mixed movements regarding Gain Therapeutics. Geode Capital Management LLC has increased its stake in the company by 48.0% in the third quarter, acquiring an additional 88,236 shares, bringing its total to 271,972 shares valued at around $484,000. Renaissance Technologies LLC also expanded its position in the second quarter by 154.2%, now holding 118,700 shares valued at $152,000 after purchasing 72,000 additional shares. Furthermore, Warberg Asset Management LLC and Hohimer Wealth Management LLC have bought new positions in the company, valued at approximately $66,000 and $422,000, respectively. Overall, approximately 11.97% of Gain Therapeutics’ stock is held by hedge funds and institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc. is a biotechnology firm focused on developing innovative small molecule therapies aimed at treating various medical conditions. Their proprietary drug discovery platform, named Magellan, is designed to identify novel allosteric binding sites related to diseases and discover small molecules that target these sites to help modulate protein function, addressing the root causes of illnesses.

Stocks, Healthcare, Investing